about
Metabolomics: Bridging the Gap between Pharmaceutical Development and Population HealthClinical significance of T cell metabolic reprogramming in cancerToward precision medicine of breast cancerAntibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy.Investigation of discriminant metabolites in tamoxifen-resistant and choline kinase-alpha-downregulated breast cancer cells using 1H-nuclear magnetic resonance spectroscopy.Metabolite Profiling of Preneoplastic and Neoplastic Lesions of Oral Cavity Tissue Samples Revealed a Biomarker Pattern.Umbelliprenin is Potentially Toxic Against the HT29, CT26, MCF-7, 4T1, A172, and GL26 Cell Lines, Potentially Harmful Against Bone Marrow-Derived Stem Cells, and Non-Toxic Against Peripheral Blood Mononuclear Cells.Deferoxamine Suppresses Collagen Cleavage and Protease, Cytokine, and COL10A1 Expression and Upregulates AMPK and Krebs Cycle Genes in Human Osteoarthritic Cartilage.Elevated expression of FABP3 and FABP4 cooperatively correlates with poor prognosis in non-small cell lung cancer (NSCLC).Inhalable oridonin-loaded poly(lactic-co-glycolic)acid large porous microparticles for in situ treatment of primary non-small cell lung cancer.Validation of a network-based strategy for the optimization of combinatorial target selection in breast cancer therapy: siRNA knockdown of network targets in MDA-MB-231 cells as an in vitro model for inhibition of tumor development.Identification of the metabolic alterations associated with the multidrug resistant phenotype in cancer and their intercellular transfer mediated by extracellular vesicles.MiRNA-543 promotes osteosarcoma cell proliferation and glycolysis by partially suppressing PRMT9 and stabilizing HIF-1α protein.Roles of Wnt Target Genes in the Journey of Cancer Stem CellsTackling multidrug resistance mediated by efflux transporters in tumor-initiating cells.MicroRNAs are important regulators of drug resistance in colorectal cancer.Curcumin mediated down-regulation of αV β3 integrin and up-regulation of pyruvate dehydrogenase kinase 4 (PDK4) in Erlotinib resistant SW480 colon cancer cells.Metabolic Regulation in Mitochondria and Drug Resistance.Acquired resistance to PI3K/mTOR inhibition is associated with mitochondrial DNA mutation and glycolysis.Molecular mechanisms of drug resistance in ovarian cancer.Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers.Identification of metabolism-associated genes and pathways involved in different stages of clear cell renal cell carcinoma.The relevance of tyrosine kinase inhibitors for global metabolic pathways in cancer.The Novel Roles of Connexin Channels and Tunneling Nanotubes in Cancer Pathogenesis.Cholesterol esterification inhibition and gemcitabine synergistically suppress pancreatic ductal adenocarcinoma proliferation.Response of Cisplatin Resistant Skov-3 Cells to [Pt(-Acac)(γ-Acac)(DMS)] Treatment Revealed by a Metabolomic ¹H-NMR StudySystematic identification of non-coding pharmacogenomic landscape in cancer
P2860
Q26741270-9D09B21F-EC72-41E2-8D28-148AE527B7CEQ26741974-B56FDE27-F8FA-4475-B578-6554F2C56A1EQ28073967-37262983-D774-43EC-9653-BF212EE0B3AEQ30275229-EBC6167F-05F3-4B33-B7B0-B2CB31693AEEQ33828887-E7D70230-AC62-4E25-839F-9B83E7702745Q36221511-99FB6871-DD0C-4507-8184-E2BC9AC8BC33Q37264874-82E0BE9C-137C-4F4D-8D34-0C8BE388A614Q37500870-583C7B8A-330E-48AD-80A9-531BB709354CQ37564704-EF598617-38C0-46A5-B816-C2D9562B9BB2Q37587394-E4791510-874F-4929-8FE3-7C0513A0FD99Q37665293-D1BE908B-E4C7-4D53-B551-DB64BF7F0D79Q37708100-B0E728E7-BD10-49F5-9AB4-142A148B5B00Q37709281-0A3A2FF9-4047-4DE3-A411-72769272D5ECQ38557075-C02938D5-6CD7-4957-86BA-2757234CD010Q38818023-65B80A6A-A68B-46F0-B431-A1712029778CQ39016759-F838B400-D76F-4949-B001-AE3F43D032D5Q45874922-29F49158-B6E8-4D4C-A12D-3532B0F04E30Q46609962-904AC1C7-7907-4E30-821B-2236C9099A25Q47143132-2ED4A340-F1E7-43DD-800E-8E1FBFCAD759Q48274587-984B7619-4B86-4B20-AD64-4495EDB51A4CQ48310841-9E8A7DFE-9F1A-48D4-9515-037E71CCFEABQ49668843-67E6144E-1D12-4FC2-AA88-FC37E7B2FBB7Q49887915-FD8093C7-2E0D-46CC-8F9F-7574B92ECCC6Q52563269-EF79E1F8-A492-4313-852D-A41397E55588Q52681396-186857C3-0A65-4A34-B895-F1F0D64A0C8FQ58691893-C0339800-CBE3-4BB5-BFFD-D1366A04B1D1Q58793778-D02A1BA6-BC49-46B5-B21D-E096C3FAF2CA
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Cancer Metabolism and Drug Resistance
@ast
Cancer Metabolism and Drug Resistance
@en
Cancer Metabolism and Drug Resistance
@nl
type
label
Cancer Metabolism and Drug Resistance
@ast
Cancer Metabolism and Drug Resistance
@en
Cancer Metabolism and Drug Resistance
@nl
prefLabel
Cancer Metabolism and Drug Resistance
@ast
Cancer Metabolism and Drug Resistance
@en
Cancer Metabolism and Drug Resistance
@nl
P2860
P3181
P356
P1433
P1476
Cancer Metabolism and Drug Resistance
@en
P2093
Mahbuba Rahman
Mohammad Rubayet Hasan
P2860
P304
P3181
P356
10.3390/METABO5040571
P407
P577
2015-01-01T00:00:00Z